BIOCRYST PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.16 USD | 0.00% |
|
-6.09% | -30.55% |
| Sales 2024 * | 395M 540M | Sales 2025 * | 484M 662M | Capitalization | 858M 1.17B |
|---|---|---|---|---|---|
| Net income 2024 * | -128M -175M | Net income 2025 * | -65M -88.85M | EV / Sales 2024 * | 2.76 x |
| Net Debt 2024 * | 234M 320M | Net Debt 2025 * | 259M 354M | EV / Sales 2025 * | 2.31 x |
| P/E ratio 2024 * |
-6.6
x | P/E ratio 2025 * |
-12
x | Employees | 536 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioCryst Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 week | -6.09% | ||
| Current month | -18.11% | ||
| 1 month | -19.22% | ||
| 3 months | -23.53% | ||
| 6 months | -21.66% | ||
| Current year | -30.55% |
1 week
4.03
4.63
1 month
4.035.16
Current year
4.037.75
1 year
4.039.07
3 years
4.0319.99
5 years
1.3819.99
10 years
1.3819.99
| Managers | Title | Age | Since |
|---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 20-04-01 |
Ryan Arnold
CTO | Chief Tech/Sci/R&D Officer | - | 22-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 20-02-26 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
| Director/Board Member | 60 | 21-07-25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.23% | 0 M€ | 0.00% | - | |
| 0.20% | 0 M€ | 0.00% | - | |
| 0.18% | 1,026 M€ | +6.95% | - | |
| 0.13% | 509 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4.16 | 0.00% | 2,310,948 |
| 24-04-25 | 4.16 | -1.19% | 2,735,562 |
| 24-04-24 | 4.21 | -3.88% | 4,409,981 |
| 24-04-23 | 4.38 | -0.68% | 4,236,664 |
| 24-04-22 | 4.41 | -0.45% | 2,557,483 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotes
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Calendar
2024-05-06
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
4.16
USD
Average target price
12.2
USD
Spread / Average Target
+193.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.55% | 858M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BCRX Stock
